Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine

Trial Profile

Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2017

At a glance

  • Drugs Hepatitis B immune globulin (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Biotest Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top